Herceptin Hylecta Injection, Solution
Product Images NDC 50242-077

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Herceptin Hylecta (NDC 50242-077). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Herceptin 01)

A Kaplan-Meier survival curve graph illustrating 'Disease-Free Survival (years)' on the x-axis and the 'Proportion Event-Free' on the y-axis. The graph compares two treatment groups over approximately 3.5 years: one with AC followed by TH (doxorubicin + cyclophosphamide followed by paclitaxel + Herceptin) represented by a dashed line, and the other with AC followed by T (doxorubicin + cyclophosphamide followed by paclitaxel) represented by a solid line. Tabulated numbers at risk for each group are shown below the x-axis.*

FDA Label Image

Figure 2 (Herceptin 02)

A survival curve chart depicting overall survival over 11 years, comparing two treatment regimens: AC->T (doxorubicin + cyclophosphamide followed by paclitaxel) shown with a solid line, and AC->T + H (same regimen plus Herceptin) shown with a dashed line. The chart includes the proportion of patients alive on the y-axis and survival time in years on the x-axis, with accompanying risk numbers beneath the graph.*

FDA Label Image

Figure 3 (Herceptin 03)

A Kaplan-Meier curve chart depicting disease-free survival over 5 years for three treatment regimens involving Herceptin (trastuzumab). The curves represent AC->TH (doxorubicin, cyclophosphamide, then docetaxel plus Herceptin), TCH (docetaxel, carboplatin plus Herceptin), and AC->T (doxorubicin, cyclophosphamide then docetaxel) cohorts. The Y-axis shows the proportion event-free, and the X-axis shows disease-free survival in years, with the number at risk shown below.*

FDA Label Image

Principal Display Panel (600 mg/10,000 unit Vial Carton)

Herceptin Hylecta injection label showing 600 mg and 10,000 units per 5 mL strength. The label states this single-dose vial is for subcutaneous use only and should have unused portions discarded. It is manufactured by Genentech, Inc. and the NDC is 50242-077-01.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.